Onze Lieve Vrouwen Gasthuis
- Address
- PO box 95500, Amsterdam, The Netherlands
Female Urogenital Diseases and Pregnancy Complications
The site is evaluating preventive strategies for vulvar high‑grade squamous intraepithelial lesions using HPV vaccination as an adjuvant approach after local treatment.
- Prevention of vulvar high‑grade lesions
- Adjuvant immunization post‑surgery
- Long‑term monitoring of recurrence
These studies aim to enhance women's health outcomes and reduce disease burden in the female urogenital tract.
Neoplasms
Research focuses on improving pain control for patients with metastatic bone pain associated with cancer spread to the skeleton.
- Analgesic optimization for bone metastasis
- Combination opioid therapy evaluation
- Quality‑of‑life enhancement for cancer patients
The program supports innovative pain relief options that can be integrated into oncology care.
Pathological Conditions, Signs and Symptoms
The centre investigates broader symptom management, emphasizing effective reduction of chronic pain across diverse conditions.
- Assessment of pain reduction strategies
- Evaluation of treatment side‑effects
- Patient‑reported outcome measures
A multidisciplinary approach ensures comprehensive care for individuals experiencing complex symptomatology.
Virus Diseases
Studies target HPV‑related disease prevention by testing the efficacy of a nonavalent vaccine in women with high‑grade vulvar lesions.
- Vaccine efficacy in high‑risk lesions
- Recurrence prevention over two years
- Monitoring of immunologic response
This work contributes to public health vaccination initiatives and aims to lower the incidence of HPV‑driven conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onze Lieve Vrouwen Gasthuis
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Adjuvant Nonavalent Human Papillomavirus Vaccination in Preventing Recurrence of Vulvar High-Grade Squamous Intraepithelial Lesion in Women | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Phase I | Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna | 1 | Unknown | 2024-03-04 | 2024-03-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.